- Raw materials
- Anti-anginal agents
- Tenitramine
Tenitramine API Manufacturers & Suppliers
0 verified results
All Tenitramine data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Tenitramine | CAS No: 21946-79-2 | GMP-certified suppliers
A medication that serves as a vasodilator aimed at improving coronary blood flow and managing myocardial ischemia in cardiac therapy applications.
Therapeutic categories
Product Snapshot
- Tenitramine is an oral small molecule formulated as a tablet
- It is primarily investigated for central nervous system indications
- The compound is currently in experimental stages and not approved by major regulatory authorities
Clinical Overview
While specific clinical indications for Tenitramine have not been established, compounds within this chemical family are generally investigated for their potential utility in cardiac therapy, particularly for conditions involving myocardial ischemia. As an organic nitrate, Tenitramine is expected to function as a vasodilator, potentially modulating cardiovascular dynamics by relaxing vascular smooth muscle and improving coronary blood flow. This mechanism is consistent with the known activity of antianginal agents that facilitate oxygen delivery to ischemic cardiac tissue.
Tenitramine’s pharmacological classification includes amines, diamines, and polyamines, indicating the presence of multiple amine functional groups that may influence its solubility, receptor interaction, and metabolic profile. However, detailed pharmacokinetic parameters, including absorption, distribution, metabolism, and excretion (ADME), have not been specified. Similarly, no direct information on its pharmacodynamics or mechanism of action beyond its classification as an organic nitrate is publicly available at this time.
Safety and toxicity data are also lacking for Tenitramine. Caution is advised when handling experimental compounds in this class, as related organic nitrates can elicit common nitrate-associated adverse effects, including hypotension, headache, and potential tolerance development upon chronic dosing.
Currently, Tenitramine remains an experimental agent without market approval or inclusion in branded pharmaceutical products. For formulation scientists and sourcing teams, procurement of Tenitramine API should prioritize suppliers compliant with Good Manufacturing Practice (GMP) standards and ensure rigorous analytical characterization to confirm chemical identity, purity, and stability due to the specialized nature and experimental status of this molecule.
Identification & chemistry
| Generic name | Tenitramine |
|---|---|
| Molecule type | Small molecule |
| CAS | 21946-79-2 |
| UNII | CKB16BAQ3S |
| DrugBank ID | DB13637 |
Formulation & handling
- Tenitramine is a small molecule alkyl nitrate typically formulated for oral administration as tablets.
- Its moderate water solubility and low LogP suggest formulation strategies should consider adequate aqueous solubility for bioavailability.
- No peptide or biologic characteristics; stability concerns focus on maintaining chemical integrity of the nitrate moiety during manufacturing and storage.
Regulatory status
Tenitramine is a type of Anti-anginal agents
Anti-anginal agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) used for the treatment of angina, a condition characterized by chest pain or discomfort caused by reduced blood flow to the heart muscle. These APIs target the underlying cause of angina, which is often related to insufficient blood supply to the heart.
One commonly used anti-anginal agent is nitroglycerin, which belongs to the class of organic nitrates. Nitroglycerin works by dilating blood vessels, including the coronary arteries that supply blood to the heart. This dilation improves blood flow to the heart, relieving chest pain and reducing the workload on the heart.
Another class of anti-anginal agents is calcium channel blockers (CCBs). CCBs inhibit the movement of calcium ions into heart muscle cells and blood vessel walls. By doing so, they relax and widen blood vessels, enhancing blood flow to the heart and reducing the frequency and severity of angina episodes.
Beta blockers are also commonly used in the treatment of angina. These agents block the effects of adrenaline and other stress hormones on the heart, resulting in reduced heart rate and blood pressure. By slowing down the heart's activity, beta blockers decrease the demand for oxygen and reduce angina symptoms.
Anti-anginal agents play a crucial role in managing angina, providing relief to patients and improving their quality of life. It is important to consult with healthcare professionals for proper diagnosis, prescription, and usage of these pharmaceutical APIs to ensure safe and effective treatment of angina.
